Sensitization Chemical Analysis Testing for Medical Devices: Standards, Methods, and Risk Assessment

Sensitization chemical analysis testing is an ISO 10993-based evaluation strategy that uses chemical characterization and toxicological risk assessment to quantify patient exposure to skin sensitizers released by medical devices, offering a scientifically robust alternative to animal-based sensitization assays. By measuring extractables such as rubber accelerators, residual monomers, preservatives, and metal ions against dermal sensitization thresholds and compound-specific safety limits, manufacturers can justify a negligible sensitization risk in regulatory submissions worldwide.

Technical Overview

Sensitization chemical analysis testing is a quantitative, chemistry-driven approach for assessing the potential of a medical device to induce allergic contact dermatitis (Type IV delayed hypersensitivity) in patients, clinicians, or other device users. Instead of relying exclusively on in vivo assays such as the guinea pig maximization test (GPMT) or the murine local lymph node assay (LLNA) described in ISO 10993-10, this strategy integrates comprehensive material and extract characterization in accordance with ISO 10993-18 with toxicological risk assessment methodologies established in ISO 10993-17.

The publication of ISO 10993-10:2021 formally recognized a risk-based, chemistry-focused route for skin sensitization evaluation, and ISO 10993-17:2023 introduced methodologies for deriving tolerable exposure levels for sensitizing constituents, including the application of the dermal sensitization threshold (DST). Under this framework, a device may be concluded to present a negligible sensitization risk when its extractables profile is adequately characterized and estimated patient exposure falls below applicable safety thresholds, thereby supporting the reduction, refinement, and replacement of animal testing (the 3Rs principles).

A typical evaluation workflow comprises the following stages:

• Review of material composition, manufacturing additives, and sterilization processes within a documented biological evaluation plan (BEP)
• Sample preparation and extraction under simulated-use and exaggerated conditions per ISO 10993-12
• Multi-instrument analytical characterization of extractables and leachables per ISO 10993-18
• Targeted quantification of known sensitizing compounds and estimation of exposure at the patient contact site
• Toxicological benchmarking against compound-specific limits, the dermal sensitization threshold, or a device-specific allowable exposure derived per ISO 10993-17
• Documentation of conclusions in a biological evaluation report (BER) consistent with the ISO 10993-1 risk management framework

Testing Samples

Skin-Contacting and Mucosal-Contacting Devices

Devices with limited, prolonged, or permanent contact with intact skin or mucosal membranes constitute the primary scope of sensitization chemical analysis. Representative examples include wound dressings, adhesive bandages, electrodes, ostomy appliances, orthopedic braces, compression garments, respiratory masks, tubing, and catheter fixation devices.

External Communicating Devices

Devices that contact breached or compromised surfaces, or that form an indirect blood path, are also evaluated, particularly where chemical residues may migrate to sensitization-relevant tissue. Examples include intravascular catheters, hemodialysis circuits, infusion sets, endoscopes, and laparoscopic instruments.

Implantable and Long-Term Contact Devices

For implants such as orthopedic fixation systems, joint prostheses, stents, and pacemaker leads, the assessment focuses on the long-term release of metal ions such as nickel, cobalt, and chromium from metallic alloys, as well as leachables from polymeric and elastomeric components.

Polymeric, Rubber, and Textile Components

Natural rubber latex and nitrile components, silicone tubing, PVC parts, seals, gaskets, and textile fabrics are frequently analyzed because they may contain residual accelerators, antioxidants, plasticizers, dyes, and finish chemicals with recognized sensitization potential.

Raw Materials, Extracts, and Process Samples

Testing may also be performed on polymer resins, adhesive formulations, curing residues, cleaning and disinfection agent residues, sterilant by-products, and packaging materials that come into contact with the finished device.

Testing Items

The analytical scope targets chemical classes with documented sensitization hazard relevant to medical device materials, as well as broad extractables and leachables (E&L) screening:

• Rubber accelerators and crosslinking agents: thiurams (TMTD, TMTM, TBTD), mercaptobenzothiazoles (MBT, MBTS, CBS), dithiocarbamates (ZDEC, ZDBC, ZMBT), thioureas, and guanidine derivatives
• Residual monomers and reactive diluents: methacrylates and acrylates (MMA, HEMA, UDMA, Bis-GMA), epoxy monomers such as DGEBA, styrene, vinyl chloride, and formaldehyde
• Elemental impurities and metal ion release: nickel, cobalt, chromium (trivalent and hexavalent), palladium, gold, and mercury, aligned with elemental impurity concepts
• Preservatives and biocides: methylisothiazolinone (MIT), methylchloroisothiazolinone (CMIT), parabens, and formaldehyde-releasing agents such as quaternium-15 and imidazolidinyl urea
• Plasticizers and heat stabilizers: phthalate esters, organotin compounds, and bisphenol A
• Antioxidants and antidegradants: hindered phenols such as BHT and Irganox-type additives, aromatic amines, and p-phenylenediamine derivatives
• Colorants, dyes, pigments, and their synthetic impurities
• Natural rubber latex proteins and associated allergens as complementary testing
• Comprehensive extractables and leachables profiling, including identification and semi-quantification of unknown organic species relative to the analytical evaluation threshold (AET)

Testing Methods

Sample Preparation and Extraction

Extraction is conducted in accordance with ISO 10993-12, using both polar vehicles (such as water or saline) and non-polar vehicles (such as n-hexane) at standardized surface-area-to-volume or mass-to-volume ratios. Simulated-use extraction supports realistic exposure estimation, while exaggerated or exhaustive extraction conditions, as described in ISO 10993-18, generate a conservative extractables profile for risk screening purposes.

Instrumental Analysis

Because device-derived sensitizers span a wide range of volatility, polarity, and concentration, a complementary analytical platform is applied:

• GC-MS and headspace GC-MS for volatile and semi-volatile organic compounds, residual monomers, and residual solvents
• LC-MS/MS and UHPLC coupled to high-resolution mass spectrometry for polar, non-volatile, and thermally labile organics, including accelerators and isothiazolinone biocides
• HPLC with UV or diode-array detection for targeted quantification of compounds such as mercaptobenzothiazole, thiurams, and formaldehyde after DNPH derivatization
• ICP-MS and ICP-OES for quantification of elemental and metal ion release, including nickel, chromium, and cobalt migration
• Ion chromatography for ionic leachables, and FTIR spectroscopy for polymer identification and comparative screening
• Colorimetric and spectrophotometric procedures, such as ASTM D7558, for quantifying dialkyldithiocarbamate, mercaptobenzothiazole, and tetramethylthiuram disulfide residues in natural rubber latex and nitrile gloves

Threshold Screening and Toxicological Risk Assessment

Detected compounds are evaluated against safety benchmarks within a structured risk assessment:

• Application of the analytical evaluation threshold (AET) per ISO 10993-18 to determine which extractables require toxicological review
• Comparison of estimated exposure against the generic dermal sensitization threshold (DST), commonly applied as 64 µg/cm² of contact area or 470 µg per device, when no compound-specific data indicate higher potency
• Derivation of compound-specific allowable exposures using no-expected-sensitization-induction levels (NESIL) or LLNA EC3 values, adjusted by sensitization assessment factors (SAF), consistent with the quantitative risk assessment logic incorporated in ISO 10993-17:2023
• Use of read-across and validated expert-rule or statistical QSAR tools to assign hazard values to data-poor or tentatively identified extractables
• Consideration of aggregate exposure, mixture effects, and device-specific contact duration, frequency, and population factors

Applications

Sensitization chemical analysis testing supports medical device safety and regulatory compliance across the full product lifecycle:

• Regulatory submissions in major jurisdictions, including biological evaluation documentation aligned with ISO 10993, EN ISO 10993, and GB/T 16886 series requirements for markets such as North America, Europe, China, and Japan
• Scientific justification for waiving in vivo sensitization studies (GPMT or LLNA) when exposure is demonstrably below established thresholds, in line with 3Rs principles
• Design-stage material selection and supplier qualification, enabling early identification of high-hazard additives such as thiuram accelerators or nickel-releasing alloys
• Change control assessments following modifications to materials, formulations, manufacturing sites, sterilization methods, or packaging
• Investigation of clinical adverse events, including contact dermatitis complaints, through targeted residue analysis and root cause determination
• Compliance verification for medical gloves and dermal-contact products where accelerator and biocide residue limits are scrutinized by regulators and purchasers

FAQ

Can chemical analysis fully replace animal sensitization tests such as the GPMT or LLNA?

Yes, in defined circumstances. ISO 10993-10:2021 permits a chemistry-based risk assessment route when the extractables profile is sufficiently complete, exposure is conservatively estimated, and all identified compounds fall below applicable thresholds. However, for devices with poorly characterized materials, incomplete extractables data, or exposures exceeding thresholds, in vivo or in vitro sensitization testing may still be required, and acceptance is ultimately determined case by case by the relevant regulatory authority or notified body.

What is the dermal sensitization threshold and when can it be used?

The DST is a generic threshold of toxicological concern for sensitization, commonly applied as 64 µg/cm² of skin contact area or 470 µg of total chemical per device. It may be applied to well-characterized extractables that do not belong to excluded high-potency chemical classes, and it is not a substitute for compound-specific assessment when robust data such as NESIL or EC3 values are available.

Which extraction conditions should be selected?

ISO 10993-12 recommends simulated-use extraction for realistic exposure estimation and exaggerated or exhaustive extraction, supported by ISO 10993-18, for conservative worst-case screening. Both polar and non-polar vehicles are generally required to ensure adequate coverage of the chemical space of potential sensitizers.

How are unknown extractables addressed in the risk assessment?

Unknowns are first screened against the analytical evaluation threshold. Extractables below the AET are excluded from toxicological review, while those above it are tentatively identified using high-resolution mass spectrometry and then evaluated using read-across, QSAR modeling, or conservative worst-case assumptions to ensure the risk conclusion remains protective.

How do the results integrate into the biological evaluation report?

The chemical analysis results, exposure estimates, and threshold comparisons are compiled into the biological evaluation report required by ISO 10993-1, forming part of a weight-of-evidence assessment that also considers cytotoxicity, irritation, genotoxicity, and material history. Accredited third-party laboratories routinely provide the analytical data and toxicological assessments needed to complete this documentation.

Is this approach accepted by regulators worldwide?

Acceptance is growing steadily. The chemistry-based route is explicitly contemplated in the current editions of ISO 10993-10 and ISO 10993-17, and regulators in North America, Europe, and Asia increasingly accept well-documented threshold-based justifications, particularly when supported by exhaustive extraction data and a transparent risk assessment rationale.